Dyne Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Great. Thanks very much, everybody, for joining. Always happy to be hosting a panel with the Dyne Therapeutics' management team. With me, I have Josh, President and CEO; Wildon, Chief Medical Officer; and Oxana, the Chief Scientific Officer.
I'm assuming most folks know the company well, but I think it will be good, Josh, maybe just for a couple of minutes to set the stage on where you're at with the DMD and DM1 programs, and then we can get into more specifics. So, thanks again for attending and please take it away.
Yeah. Thanks, Paul. As always, thanks for your partnership and inviting us here today. Before we start, I just want to remind everyone that we'll be making some forward-looking statements during our discussion, so please refer to our SEC filings for more information.
As you know, Paul, we've had a number of [progress] this year. It's an exciting time for Dyne. We anticipate our first clinical data in our co-lead programs, the DM1 and DMD
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
